Genomic Health, Inc. (NASDAQ:GHDX)

CAPS Rating: 4 out of 5

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Results 1 - 20 of 46 : 1 2 3 Next »

Recs

0
Member Avatar pchop123 (78.46) Submitted: 4/12/2014 5:50:35 PM : Outperform Start Price: $26.74 GHDX Score: +2.15

flyer

Recs

0
Member Avatar PatientJC (31.18) Submitted: 2/10/2014 11:40:55 AM : Outperform Start Price: $26.38 GHDX Score: +1.72

Superior fundamentals

Recs

0
Member Avatar marsuculix (< 20) Submitted: 1/8/2014 3:32:53 PM : Outperform Start Price: $28.39 GHDX Score: -3.76

currently - technically spoken - oversold

Recs

0
Member Avatar mevanzzz (69.96) Submitted: 11/15/2013 3:33:12 PM : Outperform Start Price: $35.40 GHDX Score: -25.24

New genetic testing technology is predictive of recurrance in patients with a few common types of cancer. The tests have the potential to greatly improve efficiencies and reduce costs in the treatment of these cancers, by allowing doctors and patients to opt-out of chemotherapy if the test results reveal that there is a low risk of reoccurance.

Recs

0
Member Avatar legofkan1 (< 20) Submitted: 11/9/2013 11:07:35 AM : Outperform Start Price: $34.98 GHDX Score: -25.92

EXPANDING!

Recs

0
Member Avatar TerryHoodSr (58.19) Submitted: 7/29/2013 11:02:13 PM : Outperform Start Price: $31.99 GHDX Score: -25.37

growth

Recs

0
Member Avatar iksnamyzs (82.70) Submitted: 1/6/2013 1:10:27 PM : Outperform Start Price: $27.75 GHDX Score: -27.78

guy on dip

Recs

1
Member Avatar FoolishDane (< 20) Submitted: 11/20/2012 9:27:36 AM : Outperform Start Price: $26.83 GHDX Score: -30.75

A single treatment won't work for everyone, so there's definite promise in a company working to perfect tests so that individualized treatments may be prescribed. This would result in less frustration for the patient and his/her family and, hopefully, better survival rates.

Recs

0
Member Avatar TMFHumbleServant (97.38) Submitted: 11/20/2012 7:38:03 AM : Outperform Start Price: $26.83 GHDX Score: -30.75

Genomics will continue to play a bigger role in the future of medicine and treatments.

Recs

0
Member Avatar poinke (99.24) Submitted: 11/7/2012 11:45:04 AM : Outperform Start Price: $28.61 GHDX Score: -36.33

Strong insider buys & strength of colon/protate cancer tests could eliminate chemo. Long

Recs

0
Member Avatar clymerjones (47.07) Submitted: 9/5/2012 10:47:49 PM : Outperform Start Price: $35.36 GHDX Score: -53.24

There is no more important health issue than getting treatments right in the fight against cancer and GHDX has the best if those tools right now. I expect their research to continue and that should them keep them in a leadership position.

Recs

0
Member Avatar saunafool (98.86) Submitted: 9/3/2012 9:25:31 AM : Outperform Start Price: $34.56 GHDX Score: -52.08

This is the future of medicine--custom treatment. Genomic Health may or may not be a winner, but I'm willing to bet some CAPS points to follow the story.

Recs

0
Member Avatar BoiseKen (94.17) Submitted: 7/3/2012 12:49:33 PM : Outperform Start Price: $35.86 GHDX Score: -58.75

I'd love to get it a little cheaper, but I think it can outperform over 5-10 years from here.

Recs

0
Member Avatar pthammond (< 20) Submitted: 6/15/2010 6:59:21 PM : Outperform Start Price: $14.38 GHDX Score: +26.36

A whole new way to diagnose that has to catch on. With limited competition, this company will do well.

Recs

1
Member Avatar gt1135 (< 20) Submitted: 2/10/2010 9:49:51 AM : Outperform Start Price: $16.95 GHDX Score: -9.80

Sitting near 52 week low. It won't last. Wish I had more real $$ to invest in this one at the moment.

Recs

1
Member Avatar simonhs (< 20) Submitted: 2/9/2010 7:28:05 PM : Outperform Start Price: $17.09 GHDX Score: -11.44

Aging population, more and more cancer. Might as well make some money off it.

Recs

1
Member Avatar scoobamang (< 20) Submitted: 11/25/2009 10:52:00 PM : Outperform Start Price: $18.80 GHDX Score: -24.18

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Recs

1
Member Avatar neilphipps (< 20) Submitted: 6/23/2009 4:31:02 PM : Outperform Start Price: $16.48 GHDX Score: -40.28

Genomics is a promising direction for genetic studies.

Recs

1
Member Avatar Cab53RobertMsnG (66.76) Submitted: 5/28/2009 2:12:13 PM : Outperform Start Price: $19.05 GHDX Score: -61.78

GHDX

Recs

1
Member Avatar jajex1 (86.37) Submitted: 5/12/2009 9:52:38 AM : Outperform Start Price: $19.66 GHDX Score: -65.89

fransgeraedts pick

Results 1 - 20 of 46 : 1 2 3 Next »

Featured Broker Partners


Advertisement